Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial
- 1 November 2018
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 26, 264-265